BACKGROUND: Although many studies have reported high early mortality among patients enrolled in antiretroviral therapy (ART) programs in sub-Saharan Africa-particularly among those individuals with advanced immunodeficiency-few studies have reported the most common causes of these early deaths. METHODS: We determined cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome (IRIS) in a well-characterized patient cohort in Kampala, Uganda, over a 36-month period of ART. RESULTS: In a cohort of patients who initiated antiretroviral therapy in Uganda, we observed a high early mortality rate among patients with advanced disease. The most common causes of death were tuberculosis and cryptococcal meningitis. The contribution of immune reconstitution inflammatory syndrome to mortality was limited. CONCLUSIONS: We show a significant early mortality in our ART cohort in resource-limited settings that is driven by advanced human immunodeficiency virus disease and characterized by low CD4 cell counts. In our experience, the contribution of IRIS to this observed early mortality is limited.
BACKGROUND: Although many studies have reported high early mortality among patients enrolled in antiretroviral therapy (ART) programs in sub-Saharan Africa-particularly among those individuals with advanced immunodeficiency-few studies have reported the most common causes of these early deaths. METHODS: We determined cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome (IRIS) in a well-characterized patient cohort in Kampala, Uganda, over a 36-month period of ART. RESULTS: In a cohort of patients who initiated antiretroviral therapy in Uganda, we observed a high early mortality rate among patients with advanced disease. The most common causes of death were tuberculosis and cryptococcal meningitis. The contribution of immune reconstitution inflammatory syndrome to mortality was limited. CONCLUSIONS: We show a significant early mortality in our ART cohort in resource-limited settings that is driven by advanced human immunodeficiency virus disease and characterized by low CD4 cell counts. In our experience, the contribution of IRIS to this observed early mortality is limited.
Authors: P Ocama; B Castelnuovo; M R Kamya; G D Kirk; S J Reynolds; A Kiragga; R Colebunders; D L Thomas Journal: Int J STD AIDS Date: 2010-08 Impact factor: 1.359
Authors: Irma Hoyo-Ulloa; Pablo F Belaunzarán-Zamudio; Brenda Crabtree-Ramirez; Arturo Galindo-Fraga; María Eugenia Pérez-Aguinaga; Juan G Sierra-Madero Journal: Int J Infect Dis Date: 2011-04-13 Impact factor: 3.623
Authors: Bach Xuan Tran; Arto Ohinmaa; Anh Thuy Duong; Nhan Thi Do; Long Thanh Nguyen; Quoc Cuong Nguyen; Steve Mills; Philip Jacobs; Stan Houston Journal: Qual Life Res Date: 2011-07-06 Impact factor: 4.147
Authors: Yukari C Manabe; William Worodria; Frank van Leth; Harriet Mayanja-Kizza; Afsatou Ndama Traore; Josefo Ferro; Nadine Pakker; Matthias Frank; Martin P Grobusch; Robert Colebunders; Frank Cobelens Journal: Am J Trop Med Hyg Date: 2016-10-17 Impact factor: 2.345
Authors: Lincoln Pac; Mara Murray Horwitz; Anne Marion Namutebi; Brandon J Auerbach; Aggrey Semeere; Teddy Namulema; Miriam Schwarz; Robert Bbosa; Allan Muruta; David B Meya; Yukari C Manabe Journal: J Acquir Immune Defic Syndr Date: 2015-04-15 Impact factor: 3.731
Authors: Sabine M Hermans; Agnes N Kiragga; Petra Schaefer; Andrew Kambugu; Andy I M Hoepelman; Yukari C Manabe Journal: PLoS One Date: 2010-05-07 Impact factor: 3.240